2.90p+0.00 (+0.00%)05 Jul 2022, 16:24
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Physiomics PLC Fundamentals

Company NamePhysiomics PLCLast Updated2022-07-05
Shares in Issue97.425 mMarket Cap£2.83 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS£-0.00EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0Debt Equity Ratio0
Asset Equity Ratio1.2028Cash Equity Ratio0.7352
Quick Ratio5.8402Current Ratio5.84
Price To Book Value2.6157ROCE0

Physiomics PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Physiomics PLC Company Financials

Tangible Assets£15,700.00£11,536.00£18,438.00
Intangible Assets£3,435.00£3,864.00£1,373.00
Total Fixed Assets£19,135.00£15,400.00£19,811.00
Cash & Equivalents£1.04 m£1.05 m£405,366.00
Other Assets000
Total Assets£1.32 m£1.45 m£694,287.00
Creditors within 1 year£157,570.00£131,517.00£86,373.00
Creditors after 1 year000
Other Liabilities000
Total Liabilities£157,570.00£131,517.00£86,373.00
Net assets£1.17 m£1.31 m£607,914.00
Called up share capital£389,339.00£382,355.00£287,641.00
Share Premium£5.93 m£5.90 m£5.23 m
Profit / Loss-£336,930.00-£133,706.00-£200,749.00
Other Equity£1.17 m£1.31 m£607,914.00
Preference & Minorities000
Total Capital Employed£1.17 m£1.31 m£607,914.00
Debt Ratio000
Assets / Equity1.20281.20281.2028
Cash / Equity0.73520.73520.7352
Cash Flow202120202019
Cash from operating activities-£32,607.00-£116,370.00-£143,772.00
Cashflow before financing£11,633.00£646,909.00-£143,772.00
Increase in Cash-£4,410.00£642,494.00-£166,503.00
Cost of sales000
Gross Profit000
Operating Profit-£337,040.00-£134,385.00-£201,219.00
Pre-Tax profit-£336,930.00-£133,706.00-£200,749.00

Physiomics PLC Company Background

ActivitiesPhysiomics PLC a United Kingdom-based firm providing services to pharmaceutical companies through outsourced systems and computational biology. The company is mainly engaged in the development of models to streamline the drug discovery anddevelopment process. It focuses on the development of Virtual Tumour Clinical used to predict optimal treatment for human clinical trials; Cardiac tox prediction service used to predict unwanted toxic side effects of drug candidates, and drug combinations database, for researchers and clinicians to access literature data on pre-clinical and clinical treatments and their effects.
Latest Interim Date7 Mar 2022
Latest Fiscal Year End Date30 Sep 2021

Physiomics PLC Directors

2021-10-27Dr. Christophe D ChassagnoleExecutive Director,Chief Operating Officer
2022-02-23Dr. Paul Bernard HarperNon-Executive Director,Chairman
2007-06-30Mr. John Kingston PoolNon-Executive Director,Chairman
2006-08-29Mr. Duncan John LipscombeNon-Executive Director
2017-11-09Mr. Mark Philip ChadwickNon-Executive Director
2021-10-27Dr. James Simon MillenExecutive Director,Chairman and Chief Executive Officer

Physiomics PLC Contact Details

Company NamePhysiomics PLC
AddressThe Magdalen Centre, Robert Robinson Avenue, Oxford, OX4 4GA
Telephone+44 1865784980

Physiomics PLC Advisors

StockbrokerHybridan LLP
Phone+44 203764 2341
Fax+44 2076001586
Financial AdviserWH Ireland Ltd
Phone0161 832 2174
Fax0161 819 8897
AuditorShipleys LLP
Phone+44 2073120000
Fax+44 2073120022
BankNational Westminster Bank PLC
RegistrarCapita Asset Services
Phone+44 8716640300
Fax+44 2086392342
Financial PR AdviserCommunications Portfolio (The)
Phone020 7536 2028
StockbrokerWH Ireland Ltd
Phone0161 832 2174
Fax0161 819 8897
SolicitorTaylor Vinters
Phone+44 1223423444
Fax+44 1223423486
Nominated AdviserWH Ireland Ltd
Phone0161 832 2174
Fax0161 819 8897